Theratechnologies Inc T.TH

Where is the plan to reduce

[houbahop]

SG&A, and R&D expenses?
Anyone saw it in the PR?

Without a plan, clear and transparent, shareholder value will be wiped out before the end of the year.

The EBITDA positive objective stated earlier is to hoodwink shareholders going into the vote at  the AGM.

I expect shareholders to reelect the board like sheeps going to the slaughter house.

[Trogarzon]

After the AACR data fails to excite anyone because it's on mice again we will have now news, a market correction and high hurdle for next quarter numbers.  Nash seems DOA.  The Nasdaq issue, the dept problem.  I think the CEO has to go and be replaced by a person that can do biotech deals or mergers.  This thing will go to 50 cents before the Cancer P1 data may revive it

[Wino115]

I think you're shortchanging it. We all now it has to still prove itself in humans but the combo trials are a bit different since they are with already marketed and huge drugs out there.  If you increase their efficacy or expand their market, that's an interesting development commercially and the partner woudl be the one that will help fund that from the lab to the patient. It's